Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 601 to 615 of 883 results for community guidance

  1. Cladribine for treating active relapsing forms of multiple sclerosis (TA1053)

    Evidence-based recommendations on cladribine (Mavenclad) for treating active relapsing forms of multiple sclerosis in adults.

    Technology appraisal guidance
    Published
    15 April 2025
    View recommendations

    Sections for TA1053

  2. What is the comparative effectiveness and cost effectiveness of exercise referral schemes compared with other interventions that aim to help people to become more physically active? Relative effectiveness and cost effectiveness should be compared in controlled trials.

    determinants of health such as reducing social isolation or improving community engagement – are seen as key benefits, then they should...

    Research recommendation
    Published
    9 June 2015

  3. What factors encourage under-represented groups to participate in and complete an exercise referral scheme? What factors prevent these groups from participating? Under-represented groups include: people from black and minority ethnic groups, people with disabilities and those from lower socioeconomic groups.

    determinants of health such as reducing social isolation or improving community engagement – are seen as key benefits, then they should...

    Research recommendation
    Published
    9 June 2015

  4. What factors encourage uptake of, and adherence to, an exercise referral scheme? Factors to consider include: design, content and delivery; referral mechanisms; choice of activity; qualifications and cost of instructors. Also identify any barriers preventing participation and factors that encourage it.

    determinants of health such as reducing social isolation or improving community engagement – are seen as key benefits, then they should...

    Research recommendation
    Published
    9 June 2015

  5. Dapagliflozin for treating chronic heart failure with reduced ejection fraction (TA679)

    Evidence-based recommendations on dapagliflozin (Forxiga) for symptomatic chronic heart failure with reduced ejection fraction in adults.

    Technology appraisal guidance
    Published
    24 February 2021
    View recommendations

    Sections for TA679

  6. Public board meeting agenda and papers: July 2024

    Agenda and papers of the NICE public board meeting on 17 July 2024

  7. How to apply to join a committee

    difference in the lives of others by developing health and social care guidance that improves services. Applying is easy. Follow our...

  8. How to apply to join a committee

    difference in the lives of others by developing health and social care guidance that improves services. Applying is easy. Follow our...

  9. Digital technologies for the detection of melanoma (MIB311)

    NICE has developed a medtech innovation briefing (MIB) on digital technologies for the detection of melanoma .

    Medtech innovation briefing
    Published
    1 November 2022

  10. Virtual ward platform technologies for acute respiratory infections: early value assessment (HTG697)

    Early value assessment (EVA) guidance on virtual ward platform technologies for acute respiratory infections.

    HealthTech guidance
    Published
    12 October 2023
    View recommendations

    Sections for HTG697

  11. What interventions are effective and cost effective at raising awareness of the health risks of damp and mould in the home?

    also the Ministry of Housing, Communities and Local Government's Housing health and safety rating system operating...

    Research recommendation
    Published
    10 February 2020

  12. Epilepsies in children, young people and adults (NG217)

    This guideline covers diagnosing and managing epilepsy in children, young people and adults in primary and secondary care, and referral to tertiary services. It aims to improve diagnosis and treatment for different seizure types and epilepsy syndromes, and reduce the risks for people with epilepsy.

    NICE guideline
    Last updated
    30 January 2025

    Sections for NG217

  13. One-piece closed bags for colostomies: late-stage assessment (HTG754)

    Late stage assessment (LSA) guidance on one-piece closed bags for colostomies

    HealthTech guidance
    Published
    10 July 2025
    View recommendations

    Sections for HTG754

  14. Shared decision-making:- For people using adult mental health services, what are the key aspects of 'shared decision-making' that they prefer, and does a training programme for health and social care professionals designed around these key aspects, when compared with no training, improve service users' experience of care? A study should be undertaken to evaluate the impact on treatment choice, the experience of care and treatment effectiveness of training service users to deal with health and social care professionals assertively.

    followed by a randomised controlled trial on shared decision-making in community mental health teams (CMHTs) compared with standard...

    Research recommendation
    Published
    9 June 2015

  15. FebriDx for C-reactive protein and myxovirus resistance protein A testing (MIB224)

    NICE has developed a medtech innovation briefing (MIB) on FebriDx for C-reactive protein and myxovirus resistance protein A testing .

    Medtech innovation briefing
    Published
    26 August 2020